Nestle acquires maker of peanut allergy treatment
The food conglomerate Nestle announced this morning that it would acquire Aimmune Therapeutics, maker of a peanut allergy treatment, for $2.6 billion, STAT's Adam Feuerstein reports.
The Food and Drug Administration approved Aimmune's Palforzia in February, and the company believed it could deliver annual sales exceeding $1 billion. The coronavirus pandemic has stymied those plans, with shutdowns making it difficult if not impossible for patients to visit allergists’ offices.
Nestle, for its part, is seeking to expand its health sciences unit.
Read more.
The Food and Drug Administration approved Aimmune's Palforzia in February, and the company believed it could deliver annual sales exceeding $1 billion. The coronavirus pandemic has stymied those plans, with shutdowns making it difficult if not impossible for patients to visit allergists’ offices.
Nestle, for its part, is seeking to expand its health sciences unit.
Read more.
.png)
No hay comentarios:
Publicar un comentario